HONG KONG, Feb. 24, 2014 /PRNewswire/ -- China Cord Blood
Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood
collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services, today announced its preliminary
unaudited financial results for the third quarter and first nine
months of fiscal year 2014, which ended December 31, 2013.
Fiscal 2014 Third Quarter Highlights
- Revenues for the third quarter of fiscal 2014 increased 0.8%
year-over-year to RMB150.6 million
($24.9 million).
- New subscriber sign-ups and accumulated subscriber base reached
16,317 and 359,487, respectively.
- Gross profit increased by 2.1% year-over-year to RMB123.6 million ($20.4
million) from RMB121.1 million
in the prior year period.
- Gross margin increased to 82.0%, compared to 81.1% in the prior
year period.
- Operating income was RMB65.7
million ($10.9 million).
- Interest expense amounted to RMB21.9
million ($3.6 million), which
was largely attributable to the convertible notes issued during
fiscal 2013.
- Net income attributable to the Company's shareholders increased
by 2.7% to RMB34.6 million
($5.7 million) from RMB33.6 million in the prior year period.
- Operating cash flow for the quarter increased to RMB169.0 million ($27.9
million), compared to RMB144.1
million in the prior year period.
Fiscal 2014 Nine Month Highlights
- Revenues for the first nine months of fiscal 2014 increased
7.1% to RMB420.9 million
($69.5 million) from RMB393.1 million in the prior year period.
- New subscriber sign-ups reached 47,505 and accumulated
subscriber base expanded to 359,487.
- Gross profit increased by 9.1% year-over-year to RMB342.1 million ($56.5
million).
- Operating income increased 5.9% year-over-year to RMB167.9 million ($27.7
million).
- Interest expense amounted to RMB53.1
million ($8.8 million),
compared to RMB48.0 million in the
prior year period.
- Net income attributable to the Company's shareholders increased
3.3% to RMB92.4 million ($15.3 million), up from RMB89.4 million in the prior year period.
- Operating cash flow for the first nine months of fiscal 2014
was RMB398.6 million ($65.8 million), after taking into account the
coupon payments made to the Company's convertible note
holders.
"Overall, we continued to deliver solid business performance in
the third quarter. Although the numbers of newborns were still down
over last year's Dragon year, the company achieved sequential
quarterly growth in new subscribers and record quarterly revenue,
attributable to our upward pricing adjustment implemented in the
beginning of our current fiscal year, and from the sound execution
of our sales and marketing strategy," stated Ms. Ting Zheng, Chief
Executive Officer of China Cord Blood Corporation.
"In the third quarter, a one-time payment option remained the
preferred choice among our new subscribers which contributed to our
robust cash flow. As we approach the end of the current fiscal
year, we remained focused on completing the capacity expansion at
our Guangdong and Zhejiang facilities, which are in their final
stages. With the new facilities coming on-line in the near future,
we will strive to intensify our marketing effort and further deepen
penetration within our key operating regions."
Third Quarter and
First Nine Months Summary Ended December 31, 2012 and
2013
|
|
|
Three Months
Ended
December
31,
|
|
Nine Months
Ended
December
31,
|
|
2012
|
|
2013
|
|
2012
|
|
2013
|
(in
thousands)
|
RMB
|
|
RMB
|
US$
|
|
RMB
|
|
RMB
|
US$
|
Revenues
|
149,320
|
|
150,586
|
24,875
|
|
393,112
|
|
420,942
|
69,534
|
Gross
Profit
|
121,052
|
|
123,554
|
20,410
|
|
313,398
|
|
342,058
|
56,503
|
Operating
Income
|
67,125
|
|
65,743
|
10,860
|
|
158,567
|
|
167,913
|
27,736
|
Net Income
Attributable to the
Company's Shareholders
|
33,631
|
|
34,554
|
5,708
|
|
89,419
|
|
92,364
|
15,256
|
Earnings per Ordinary
Shares
– Basic[1] and Diluted (RMB/US$)
|
0.42
|
|
0.41
|
0.07
|
|
1.17
|
|
1.14
|
0.19
|
|
|
|
|
|
|
|
|
|
|
Revenue Breakdown
(%)
|
|
|
|
|
|
|
|
|
|
Processing
Fees
|
77.4%
|
|
71.3%
|
|
|
76.5%
|
|
70.9%
|
|
Storage
Fees
|
22.6%
|
|
28.7%
|
|
|
23.5%
|
|
29.1%
|
|
|
|
|
|
|
|
|
|
|
|
New Subscribers
(persons)
|
21,218
|
|
16,317
|
|
|
56,169
|
|
47,505
|
|
Total Accumulated
Subscribers
(persons)
|
295,923
|
|
359,487
|
|
|
295,923
|
|
359,487
|
|
|
|
|
|
|
|
|
|
|
|
[1] The terms of the
convertible notes issued to KKR China Healthcare Investment Limited
("KKR") and Golden Meditech Holdings Limited ("Golden Meditech")
provide each party with the ability to participate in any excess
cash dividend. Therefore, the calculation of basic EPS has taken
into consideration the effect of such participating rights of
RMB0.07 ($0.01) and RMB0.13 ($0.02) for the three months and nine
months ended December 31, 2013, respectively.
|
Summary -
Selected Cash Flow Statement Items
|
|
|
|
|
|
Three Months
Ended
|
|
Nine Months
Ended
|
|
December 31,
2013
|
|
December 31,
2013
|
(in
thousands)
|
RMB
|
US$
|
|
RMB
|
US$
|
Net cash provided by
operating
activities
|
168,993
|
27,916
|
|
398,616
|
65,846
|
Net cash used in
investing activities
|
(83,955)
|
(13,868)
|
|
(140,846)
|
(23,266)
|
Net cash provided by
financing activities
|
-
|
-
|
|
2,336
|
386
|
Third Quarter of Fiscal 2014 Financial Results
REVENUES. Revenues increased by 0.8% to
RMB150.6 million ($24.9 million) in the third quarter of fiscal
2014 from RMB149.3 million in the
prior year period, driven mainly by higher service fees implemented
since the first quarter of fiscal 2014 and the increased
contribution of storage revenue from the Company's expanded
accumulated subscriber base, offset in part by the year-over-year
decline in new subscriber numbers due to the Dragon year
after-effect. The Company's growing subscriber base and
quarter-over-quarter improvement in new subscriber numbers led to a
6.3% sequential increase in revenues from the fiscal 2014 second
quarter.
Revenues generated from storage fees increased to RMB43.2 million ($7.1
million), up 27.8% from RMB33.8
million in the prior year period. Because of the increased
accumulated subscriber base, revenue from storage fees accounted
for 28.7% of total revenues, compared to 22.6% in the prior year
period.
Revenues generated from processing fees in this quarter were
RMB107.4 million ($17.8 million), down from RMB115.5 million in the prior year period as
pricing increases offset part of the impact of year-over-year
declines in new subscriber numbers. 16,317 new subscriber sign-ups
were recorded during the third quarter of fiscal 2014, representing
a 23.1% year-over-year decrease but a 2.4% sequential increase.
Revenues generated from processing fees accounted for 71.3% of
total revenues, compared to 77.4% in the prior year period.
GROSS PROFIT. Gross profit for the third quarter
of fiscal 2014 increased by 2.1% to RMB123.6
million ($20.4 million) from
RMB121.1 million in the prior year
period. Gross margin continued to improve to 82.0%, compared to
81.1% in the prior year period, as the Company benefitted from
increased storage revenue as a percent of the overall revenue mix
and slightly improved economies of scale.
OPERATING INCOME. Operating income for the third
quarter was RMB65.7 million
($10.9 million), compared to
RMB67.1 million in the prior year
period. Operating margin decreased to 43.7% from 45.0% in the prior
year period. The decrease was mainly due to higher promotion and
depreciation expenses. Depreciation and amortization expenses for
the third quarter increased to RMB9.9
million ($1.6 million), from
RMB8.4 million in the prior year
period as the Company's facility expansion programs gradually reach
completion.
Research and Development Expenses. Research and
development expenses remained stable at RMB2.4 million ($0.4
million).
Sales and Marketing Expenses. Sales and marketing
expenses for the third quarter amounted to RMB28.2 million ($4.7
million), compared to RMB24.8
million in the prior year period. The increase in sales
and marketing expenses relates to the effort to attract
new subscribers following the Dragon year. Additional expenses
were incurred for the implementation of a more extensive marketing
plan for the Zhejiang market. This
was offset by various cost control measures enforced by the
management. As a result, while fiscal 2014 third quarter sales
and marketing expenses as a percentage of revenue increased to
18.7% from 16.6% in the prior year period, they showed a sequential
improvement from 19.5% in the second quarter of the current fiscal
year.
General and Administrative Expenses. General and
administrative expenses were stable at RMB27.2 million ($4.5
million), compared to RMB27.0
million in the prior year period and RMB28.0 million in the second quarter of fiscal
2014. As a percentage of revenue, general and administrative
expenses were 18.1%, similar to the prior year period, and an
improvement from 19.8% in the second quarter of fiscal 2014.
OTHER INCOME AND EXPENSES
Interest Expense. Interest expense decreased to
RMB21.9 million ($3.6 million) from RMB23.8
million in the prior year period. The decrease was largely
attributable to the capitalization of interest expense for the
Company's in-progress construction of new facilities. Interest
expense capitalized in the third quarter of fiscal 2014 amounted to
RMB3.6 million ($0.6 million). No interest expense was
capitalized in the prior year period.
NET INCOME ATTRIBUTABLE TO THE COMPANY'S
SHAREHOLDERS. As the increase in income before tax was
partially offset by the increase in income tax expense, net income
attributable to the Company's shareholders for the third quarter of
fiscal 2014 increased to RMB34.6
million ($5.7 million) from
RMB33.6 million in the prior year
period. Net margin for the third quarter of fiscal 2014 was 22.9%,
slightly higher than 22.5% for the same period last year and 17.6%
for the second quarter of the current fiscal year.
EARNINGS PER SHARE. The terms of the convertible
notes issued to KKR and Golden Meditech provide each party with the
ability to participate in any Excess Cash Dividend[2]. Therefore,
the calculation of basic and diluted EPS incorporates the effect of
such participating rights of RMB0.07
($0.01). Basic and diluted earnings
per ordinary share for the third quarter of fiscal 2014 were
RMB0.41 ($0.07).
LIQUIDITY. As of December
31, 2013, the Company had cash and cash equivalents of
RMB1,754.6 million ($289.8 million) compared to RMB1,494.1 million as of March 31, 2013. The Company had total debt of
RMB821.8 million ($135.8 million) as of December 31, 2013. Operating cash flow for the
quarter amounted to RMB169.0 million
($27.9 million).
[2]"Excess Cash
Dividend" means any cash dividend to holders of shares that,
together with all other cash dividends previously paid to holders
of shares in the same financial year, exceeds, on a per share
basis, an amount equal to the interest that has accrued and shall
accrue at 7% in such financial year divided by the number of shares
into which the note is convertible at the conversion price then in
effect on the relevant record date.
|
First Nine Months of Fiscal 2014 Financial Results
For the first nine months of fiscal year 2014, total revenues
increased 7.1% to RMB420.9 million
($69.5 million) from RMB393.1 million in the prior year period. The
increase was largely attributable to the implementation of the
Company's higher service pricing fee and the expansion of the
Company's accumulated subscriber base to 359,487 subscribers, which
outweighed the impact of the decrease in new subscriber numbers
after the Dragon year. Revenues from processing fees decreased
slightly by 0.8% but storage fees grew by 32.7%. Gross profit
increased by 9.1% to RMB342.1 million
($56.5 million) from RMB313.4 million in the prior year period.
Operating income increased by 5.9% to RMB167.9 million ($27.7
million) from RMB158.6 million
in the prior year period. Net income attributable to the Company's
shareholders totaled RMB92.4 million
($15.3 million). Basic and diluted
earnings per share attributable to ordinary shares were
RMB1.14 ($0.19). Net cash provided by operating
activities in the first nine months of fiscal 2014 was RMB398.6 million ($65.8
million).
Conference Call
The Company will host a conference call at 8:00 a.m. ET on Tuesday,
February 25, 2014 to discuss its financial performance and
give a brief overview of the Company's recent developments,
followed by a question and answer session. Interested parties may
access the audio webcast through the Company's IR website at
http://ir.chinacordbloodcorp.com. A replay of the webcast will be
accessible two hours after the conference call and available for
three weeks at the same URL link above. Listeners may also access
the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers
or +852-5808-3202 for Hong Kong
callers, access code: 2926250.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses. Under
current PRC government regulations, only one licensed cord blood
banking operator is permitted to operate in each licensed region
and only seven licenses have been authorized as of today. China
Cord Blood Corporation provides cord blood collection, laboratory
testing, hematopoietic stem cell processing and stem cell storage
services. For more information, please visit our website at
http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934. These
statements relate to future events or the Company's future
financial performance. The Company has attempted to identify
forward-looking statements by terminology including "anticipates",
"believes", "expects", "can", "continue", "could", "estimates",
"intends", "may", "plans", "potential", "predict", "should" or
"will" or the negative of these terms or other comparable
terminology. These statements are only predictions, uncertainties
and other factors may cause the Company's actual results, levels of
activity, performance or achievements to be materially different
from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking
statements. The information in this press release is not intended
to project future performance of the Company. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, the Company does not guarantee future
results, levels of activity, performance or achievements. The
Company expectations are as of the date this press release is
issued, and the Company does not intend to update any of the
forward-looking statements after the date this press release is
issued to confirm these statements to actual results, unless
required by law.
The forward-looking statements included in this press release
are subject to risks, uncertainties and assumptions about the
Company's businesses and business environments. These statements
reflect the Company's current views with respect to future events
and are not a guarantee of future performance. Actual results of
the Company's operations may differ materially from information
contained in the forward-looking statements as a result of risk
factors some of which include, among other things: continued
compliance with government regulations regarding cord blood banking
in the People's Republic of China,
or PRC and any other jurisdiction in which the Company conducts its
operations; changing legislation or regulatory environments in the
PRC and any other jurisdiction in which the Company conducts its
operations; the acceptance by subscribers of the Company's
different pricing and payment options and reaction to the
introduction of the Company's premium-quality pricing strategy;
demographic trends in the regions of the PRC in which the Company
is the exclusive licensed cord blood banking operator; labor and
personnel relations; the existence of a significant shareholder
able to influence and direct the corporate policies of the Company;
credit risks affecting the Company's revenue and profitability;
changes in the healthcare industry, including those which may
result in the use of stem cell therapies becoming redundant or
obsolete; the Company's ability to effectively manage its growth,
including implementing effective controls and procedures and
attracting and retaining key management and personnel; changing
interpretations of generally accepted accounting principles; the
availability of capital resources, including in the form of capital
markets financing opportunities, in light of industry developments
affecting issuers that have pursued a "reverse merger" with an
operating company based in China,
as well as general economic conditions; compliance with restrictive
debt covenants under our senior convertible notes; and other
relevant risks detailed in the Company's filings with the
Securities and Exchange Commission in the
United States.
This announcement contains translations of certain Renminbi
amounts into U.S. dollars at specified rates solely for the
convenience of readers. Unless otherwise noted, all translations
from Renminbi to U.S. dollars as of and for the periods ending
December 31, 2013 were made at the
noon buying rate of RMB6.0537 to
$1.00 on December 31, 2013 in the City of New York for cable transfers in
Renminbi per U.S. dollar as certified for customs purposes by the
Federal Reserve Bank of New York.
China Cord Blood Corporation makes no representation that the
Renminbi or U.S. dollar amounts referred to in this press release
could have been or could be converted into U.S. dollars or
Renminbi, at any particular rate or at all.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com
EXHIBIT 1
CHINA CORD BLOOD
CORPORATION
|
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
|
As of March 31 and
December 31, 2013
|
|
|
|
|
|
|
March 31,
|
|
December
31,
|
|
|
2013
|
|
2013
|
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
(in thousands except
share data)
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash and cash
equivalents
|
1,494,099
|
|
1,754,558
|
|
289,832
|
Accounts receivable,
less allowance for doubtful accounts
|
|
|
|
|
|
(March 31,
2013: RMB14,112; December 31, 2013: RMB17,137)
|
73,076
|
|
86,361
|
|
14,266
|
Inventories
|
10,265
|
|
23,319
|
|
3,852
|
Prepaid expenses and
other receivables
|
11,602
|
|
20,991
|
|
3,466
|
Debt issuance
costs
|
3,678
|
|
3,587
|
|
593
|
Deferred tax
assets
|
5,454
|
|
6,493
|
|
1,073
|
Total current
assets
|
1,598,174
|
|
1,895,309
|
|
313,082
|
Property, plant and
equipment, net
|
468,272
|
|
600,413
|
|
99,182
|
Non-current
prepayments
|
212,633
|
|
210,582
|
|
34,786
|
Non-current accounts
receivable, less allowance for doubtful accounts
|
|
|
|
|
|
(March 31, 2013:
RMB36,361; December 31, 2013: RMB36,817)
|
249,370
|
|
234,838
|
|
38,792
|
Inventories
|
39,730
|
|
46,228
|
|
7,636
|
Intangible assets,
net
|
125,170
|
|
121,704
|
|
20,104
|
Available-for-sale
equity securities
|
88,404
|
|
149,408
|
|
24,680
|
Other
investment
|
189,129
|
|
189,129
|
|
31,242
|
Debt issuance
costs
|
11,667
|
|
8,676
|
|
1,433
|
Deferred tax
assets
|
3,727
|
|
1,416
|
|
234
|
Total
assets
|
2,986,276
|
|
3,457,703
|
|
571,171
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Bank loan
|
50,000
|
|
60,000
|
|
9,911
|
Accounts
payable
|
9,890
|
|
11,999
|
|
1,982
|
Accrued expenses and
other payables
|
84,006
|
|
88,136
|
|
14,560
|
Deferred
revenue
|
172,328
|
|
180,767
|
|
29,861
|
Amounts due to
related parties
|
11,241
|
|
12,146
|
|
2,006
|
Income tax
payable
|
4,983
|
|
2,444
|
|
404
|
Deferred tax
liabilities
|
-
|
|
2,600
|
|
429
|
Total current
liabilities
|
332,448
|
|
358,092
|
|
59,153
|
Convertible
notes
|
751,781
|
|
761,816
|
|
125,843
|
Non-current deferred
revenue
|
530,258
|
|
750,213
|
|
123,926
|
Other non-current
liabilities
|
107,158
|
|
150,390
|
|
24,843
|
Deferred tax
liabilities
|
23,168
|
|
26,866
|
|
4,438
|
Total
liabilities
|
1,744,813
|
|
2,047,377
|
|
338,203
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
|
Shareholders'
equity of China Cord Blood Corporation
|
|
|
|
|
|
Ordinary
shares
|
|
|
|
|
|
- US$0.0001 par
value, 250,000,000 shares authorized,
|
|
|
|
|
|
73,140,147 shares issued,
and 73,003,248 shares outstanding
|
|
|
|
|
|
as of March 31, 2013 and
December 31, 2013, respectively
|
50
|
|
50
|
|
8
|
Additional paid-in
capital
|
798,221
|
|
798,221
|
|
131,857
|
Treasury stock, at
cost
|
|
|
|
|
|
(March 31,
2013 and December 31, 2013: 136,899 shares,
respectively)
|
(2,815)
|
|
(2,815)
|
|
(465)
|
Accumulated other
comprehensive income
|
18,256
|
|
94,295
|
|
15,576
|
Retained
earnings
|
423,420
|
|
515,784
|
|
85,201
|
Total equity
attributable to China Cord Blood Corporation
|
1,237,132
|
|
1,405,535
|
|
232,177
|
Non-controlling
interests
|
4,331
|
|
4,791
|
|
791
|
Total
equity
|
1,241,463
|
|
1,410,326
|
|
232,968
|
Total liabilities
and equity
|
2,986,276
|
|
3,457,703
|
|
571,171
|
|
|
|
|
|
|
EXHIBIT 2
CHINA CORD BLOOD
CORPORATION
|
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
INCOME
|
For the Three Months
and Nine Months ended December 31, 2012 and 2013
|
|
|
|
|
|
Three months ended
December 31,
|
Nine months ended
December 31,
|
|
2012
|
|
2013
|
|
2012
|
|
2013
|
|
RMB
|
|
RMB
|
|
US$
|
|
RMB
|
|
RMB
|
|
US$
|
|
(in thousands except
share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
149,320
|
|
150,586
|
|
24,875
|
|
393,112
|
|
420,942
|
|
69,534
|
Direct
costs
|
(28,268)
|
|
(27,032)
|
|
(4,465)
|
|
(79,714)
|
|
(78,884)
|
|
(13,031)
|
Gross
profit
|
121,052
|
|
123,554
|
|
20,410
|
|
313,398
|
|
342,058
|
|
56,503
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
(2,087)
|
|
(2,401)
|
|
(397)
|
|
(6,210)
|
|
(7,234)
|
|
(1,195)
|
Sales and
marketing
|
(24,831)
|
|
(28,217)
|
|
(4,661)
|
|
(67,568)
|
|
(84,274)
|
|
(13,921)
|
General and
administrative
|
(27,009)
|
|
(27,193)
|
|
(4,492)
|
|
(81,053)
|
|
(82,637)
|
|
(13,651)
|
Total operating
expenses
|
(53,927)
|
|
(57,811)
|
|
(9,550)
|
|
(154,831)
|
|
(174,145)
|
|
(28,767)
|
Operating
income
|
67,125
|
|
65,743
|
|
10,860
|
|
158,567
|
|
167,913
|
|
27,736
|
Other expense,
net
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
3,874
|
|
3,761
|
|
621
|
|
11,062
|
|
12,255
|
|
2,024
|
Interest
expense
|
(23,762)
|
|
(21,866)
|
|
(3,612)
|
|
(48,027)
|
|
(53,085)
|
|
(8,769)
|
Exchange
loss
|
(1,010)
|
|
(194)
|
|
(32)
|
|
(959)
|
|
(249)
|
|
(41)
|
Dividend
income
|
2,265
|
|
1,189
|
|
196
|
|
4,685
|
|
9,911
|
|
1,637
|
Others
|
45
|
|
603
|
|
100
|
|
(721)
|
|
1,647
|
|
272
|
Total other expense,
net
|
(18,588)
|
|
(16,507)
|
|
(2,727)
|
|
(33,960)
|
|
(29,521)
|
|
(4,877)
|
Income before
income tax
|
48,537
|
|
49,236
|
|
8,133
|
|
124,607
|
|
138,392
|
|
22,859
|
Income tax
expense
|
(13,259)
|
|
(14,489)
|
|
(2,393)
|
|
(28,060)
|
|
(45,568)
|
|
(7,527)
|
Net
income
|
35,278
|
|
34,747
|
|
5,740
|
|
96,547
|
|
92,824
|
|
15,332
|
Net income
attributable to non-
controlling interests
|
(1,647)
|
|
(193)
|
|
(32)
|
|
(7,128)
|
|
(460)
|
|
(76)
|
Net income
attributable to China
Cord Blood Corporation's
shareholders
|
33,631
|
|
34,554
|
|
5,708
|
|
89,419
|
|
92,364
|
|
15,256
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per
share:
|
|
|
|
|
|
|
|
|
|
|
|
Attributable to
ordinary shares
|
|
|
|
|
|
|
|
|
|
|
|
-
Basic
|
0.42
|
|
0.41
|
|
0.07
|
|
1.17
|
|
1.14
|
|
0.19
|
-
Diluted
|
0.42
|
|
0.41
|
|
0.07
|
|
1.17
|
|
1.14
|
|
0.19
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
- Net effect of
foreign currency
translation, net of nil tax
|
784
|
|
2,391
|
|
395
|
|
(1,640)
|
|
11,985
|
|
1,980
|
- Net unrealized
(loss)/gain in
available-for-sale equity securities,
net of nil tax
|
(1,193)
|
|
(19,504)
|
|
(3,222)
|
|
(21,143)
|
|
64,054
|
|
10,581
|
Comprehensive
income
|
34,869
|
|
17,634
|
|
2,913
|
|
73,764
|
|
168,863
|
|
27,893
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
attributable
to non-controlling interests
|
(1,646)
|
|
(193)
|
|
(32)
|
|
(7,105)
|
|
(460)
|
|
(76)
|
Comprehensive
income
attributable to China Cord Blood
Corporation's shareholders
|
33,223
|
|
17,441
|
|
2,881
|
|
66,659
|
|
168,403
|
|
27,817
|
SOURCE China Cord Blood Corporation